Architecting the Future: The Evolution of IT Landscape in the Biopharma Industry

Author(s)Partha Anbil , Anoop Sidharthan

As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.

The biopharmaceutical industry is undergoing a profound transformation driven by rapid technological advancements, shifting demographics, and stringent regulatory environments. As organizations face unprecedented pressure to accelerate drug discovery, reduce costs, and improve patient outcomes, the role of information technology (IT) has shifted fundamentally.

Related to this article

October 26th, 2026

The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis

Merck and Kelun’s sac-TMT extends overall survival in pretreated endometrial cancer, Bristol Myers Squibb reports interim data and a patient death in its phase 1 CAR-T trial in multiple sclerosis, and BioNTech and DualityBio’s HER2 ADC meets its phase 3 goal but with limited expected benefit.

Public speaking backgrounds, Close-up the microphone on stand for speaker speech at seminar room with technology light background and blur bokeh. | Image credit: © Eakrin - © Eakrin - stock.adobe.com

October 26th, 2026

David Berry to Close AAPS PharmSci 360 on Pharma Entrepreneurship

This year's PharmSci 360 will close with a plenary on fixing drug development economics given by Averin's Dr Berry.

October 26th, 2026

How Lipid-Based Softgels Protect Oral Peptides from Degradation

Dr Karunakar Sukuru of Catalent explains how lipid-based softgels address physiological barriers to oral peptide delivery as approvals increase.

3D illustration of a translucent human pelvis with the uterus, fallopian tubes, ovaries, cervix, and vagina highlighted in orange against a blue background. | Image Credit: © magicmine - stock.adobe.com

October 26th, 2026

Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer

Full Phase 3 TroFuse-005 data presented at ESMO 2026 show the TROP2-directed ADC sacituzumab tirumotecan cut the risk of death by 32% vs chemotherapy, and an FDA decision is expected by June 2027.

Doctor examining MRI images of patient with multiple sclerosis at table in clinic, closeup | Image credit: © New Africa - © New Africa - stock.adobe.com

October 26th, 2026

BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study

A patient with relapsing MS died of septic pneumonia 44 days after zola-cel CAR T infusion, as all 60 dose level 2 patients stayed off DMTs.

3D illustration of a white Y-shaped antibody with red molecules attached to its stem and lower arms, against a dark, blurred background. | Image Credit: © AddMeshCube - stock.adobe.com

October 26th, 2026

BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit

BioNTech and DualityBio's HER2-directed ADC modestly improved progression-free survival over chemotherapy in DYNASTY-Breast02, but higher interstitial lung disease rates and an established competitor limit its potential in this setting.

October 26th, 2026

Cell Culture Media is the Biggest Target in the Push for $10-per-Gram Antibodies, Says IIT Delhi’s Anurag Rathore

Anurag Rathore, PhD, professor of chemical engineering at IIT Delhi, explains how his team is making antibody manufacturing more efficient and replacing costly raw materials to cut monoclonal antibody costs to about $10 per gram.

The approval lets adults with moderate-to-severe Crohn’s disease start risankizumab-rzaa at home, supported by phase 3 AFFIRM results at week 12. Credit: Stock.Adobe.com/Matthieu

October 23rd, 2026

FDA Approves On-Body Injector Induction for Skyrizi in Crohn's Disease

The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.